Biodexa Pharmaceuticals - Wutah dodolan YoY sajrone 12 wulan kepungkur BDRX

Logo grafis biodexapharma.com (BDRX)

Biodexa Pharmaceuticals (BDRX) maintains a protected patent margin based on the development of complex generics for brain treatment. The current YoY TTM revenue growth rate, which the GURU.Markets service illustrates in this chart, is accompanied by the value 0.00, characterizing this valuation parameter. However, the company allocates resources to laboratories without scaling, although its unique drug delivery methods help combat rare cancers.

BDRX Biodexa Pharmaceuticals: Wutah pendapatan YoY sajrone 12 wulan kepungkur ing interval 11.02.2024 - 18.11.2026

Biodexa Pharmaceuticals (BDRX) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:
Ringkesan analitik perusahaan:BDRX (Biodexa Pharmaceuticals PLC)
Produk dadi Biodexa Pharma

Biodexa Pharmaceuticals focuses on developing advanced drug delivery systems across the blood-brain barrier for the therapy of rare brain oncopathologies. Analyzing the rolling 12-month sales growth relative to the previous year allows for an assessment of the net annual revenue increase, which helps investors distinguish short-term volatility from sustainable business scaling and minimize portfolio drawdown risks.